nodes	percent_of_prediction	percent_of_DWPC	metapath
Tramadol—CYP2B6—Cholecalciferol—psoriasis	0.0711	0.157	CbGbCtD
Tramadol—CYP2D6—Hydroxyurea—psoriasis	0.0567	0.125	CbGbCtD
Tramadol—CYP3A4—Calcitriol—psoriasis	0.0424	0.0938	CbGbCtD
Tramadol—CYP2D6—Cholecalciferol—psoriasis	0.0344	0.076	CbGbCtD
Tramadol—CYP3A4—Methoxsalen—psoriasis	0.033	0.073	CbGbCtD
Tramadol—CYP2B6—Dexamethasone—psoriasis	0.0308	0.0681	CbGbCtD
Tramadol—CYP2D6—Cyclosporine—psoriasis	0.0226	0.05	CbGbCtD
Tramadol—CYP3A4—Cholecalciferol—psoriasis	0.0218	0.0483	CbGbCtD
Tramadol—CYP3A4—Mycophenolate mofetil—psoriasis	0.0189	0.0419	CbGbCtD
Tramadol—CYP3A4—Triamcinolone—psoriasis	0.0189	0.0419	CbGbCtD
Tramadol—CYP3A4—Betamethasone—psoriasis	0.0162	0.036	CbGbCtD
Tramadol—CYP3A4—Prednisolone—psoriasis	0.016	0.0355	CbGbCtD
Tramadol—CYP3A4—Hydrocortisone—psoriasis	0.0152	0.0336	CbGbCtD
Tramadol—CYP3A4—Prednisone—psoriasis	0.0151	0.0335	CbGbCtD
Tramadol—CYP2D6—Dexamethasone—psoriasis	0.0149	0.0329	CbGbCtD
Tramadol—CYP3A4—Cyclosporine—psoriasis	0.0144	0.0318	CbGbCtD
Tramadol—CYP3A4—Dexamethasone—psoriasis	0.00945	0.0209	CbGbCtD
Tramadol—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000762	0.0481	CbGpPWpGaD
Tramadol—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.000728	0.046	CbGpPWpGaD
Tramadol—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000506	0.032	CbGpPWpGaD
Tramadol—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000331	0.0209	CbGpPWpGaD
Tramadol—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000302	0.0191	CbGpPWpGaD
Tramadol—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000298	0.0188	CbGpPWpGaD
Tramadol—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000245	0.0155	CbGpPWpGaD
Tramadol—OPRD1—G alpha (i) signalling events—HCAR2—psoriasis	0.000238	0.015	CbGpPWpGaD
Tramadol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00021	0.0133	CbGpPWpGaD
Tramadol—OPRK1—G alpha (i) signalling events—HCAR2—psoriasis	0.000209	0.0132	CbGpPWpGaD
Tramadol—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000207	0.0131	CbGpPWpGaD
Tramadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000189	0.0119	CbGpPWpGaD
Tramadol—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.000177	0.0112	CbGpPWpGaD
Tramadol—OPRM1—G alpha (i) signalling events—HCAR2—psoriasis	0.000176	0.0111	CbGpPWpGaD
Tramadol—OPRM1—TCR Signaling Pathway—REL—psoriasis	0.00017	0.0108	CbGpPWpGaD
Tramadol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00017	0.0108	CbGpPWpGaD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000166	0.0105	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000157	0.00995	CbGpPWpGaD
Tramadol—OPRD1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000147	0.00925	CbGpPWpGaD
Tramadol—OPRM1—IL4-mediated signaling events—SOCS1—psoriasis	0.000146	0.00925	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—HCAR2—psoriasis	0.000144	0.0091	CbGpPWpGaD
Tramadol—OPRM1—TCR Signaling Pathway—IL17A—psoriasis	0.000143	0.00906	CbGpPWpGaD
Tramadol—CHRM3—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000142	0.00899	CbGpPWpGaD
Tramadol—SLC6A4—NRF2 pathway—TGFA—psoriasis	0.000141	0.00892	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00014	0.00886	CbGpPWpGaD
Tramadol—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000139	0.00877	CbGpPWpGaD
Tramadol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000137	0.00868	CbGpPWpGaD
Tramadol—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000136	0.00856	CbGpPWpGaD
Tramadol—OPRM1—IL4-mediated signaling events—IL10—psoriasis	0.000131	0.0083	CbGpPWpGaD
Tramadol—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.00013	0.00822	CbGpPWpGaD
Tramadol—OPRK1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000128	0.00811	CbGpPWpGaD
Tramadol—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000128	0.00811	CbGpPWpGaD
Tramadol—OPRM1—IL4-mediated signaling events—IL4—psoriasis	0.000128	0.00807	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—HCAR2—psoriasis	0.000126	0.00798	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—IL13—psoriasis	0.000124	0.00785	CbGpPWpGaD
Tramadol—OPRD1—G alpha (i) signalling events—CCL20—psoriasis	0.000124	0.00781	CbGpPWpGaD
Tramadol—SLC6A2—NRF2 pathway—TGFA—psoriasis	0.000121	0.00767	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.00012	0.0076	CbGpPWpGaD
Tramadol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000111	0.00704	CbGpPWpGaD
Tramadol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.00011	0.00694	CbGpPWpGaD
Tramadol—OPRM1—Peptide ligand-binding receptors—CCL20—psoriasis	0.000109	0.00686	CbGpPWpGaD
Tramadol—OPRK1—G alpha (i) signalling events—CCL20—psoriasis	0.000108	0.00685	CbGpPWpGaD
Tramadol—OPRM1—GPCR ligand binding—HCAR2—psoriasis	0.000107	0.00674	CbGpPWpGaD
Tramadol—SLC6A4—Monoamine Transport—TNF—psoriasis	0.000105	0.00664	CbGpPWpGaD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000104	0.00655	CbGpPWpGaD
Tramadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	9.83e-05	0.00621	CbGpPWpGaD
Tramadol—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.68e-05	0.00612	CbGpPWpGaD
Tramadol—OPRM1—TCR Signaling Pathway—CD8A—psoriasis	9.64e-05	0.00609	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—HCAR2—psoriasis	9.17e-05	0.00579	CbGpPWpGaD
Tramadol—OPRM1—G alpha (i) signalling events—CCL20—psoriasis	9.16e-05	0.00579	CbGpPWpGaD
Tramadol—CYP2D6—Biological oxidations—CYP2S1—psoriasis	9.05e-05	0.00572	CbGpPWpGaD
Tramadol—SLC6A2—Monoamine Transport—TNF—psoriasis	9.04e-05	0.00571	CbGpPWpGaD
Tramadol—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	8.93e-05	0.00564	CbGpPWpGaD
Tramadol—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	8.77e-05	0.00554	CbGpPWpGaD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	8.62e-05	0.00544	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—HCAR2—psoriasis	8.14e-05	0.00514	CbGpPWpGaD
Tramadol—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	8.02e-05	0.00507	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—HCAR2—psoriasis	7.89e-05	0.00499	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	7.78e-05	0.00491	CbGpPWpGaD
Tramadol—Discomfort—Dexamethasone—psoriasis	7.73e-05	0.000145	CcSEcCtD
Tramadol—Dyspepsia—Hydrocortisone—psoriasis	7.73e-05	0.000145	CcSEcCtD
Tramadol—Haemoglobin—Methotrexate—psoriasis	7.72e-05	0.000145	CcSEcCtD
Tramadol—Rash—Mycophenolic acid—psoriasis	7.7e-05	0.000145	CcSEcCtD
Tramadol—Dermatitis—Mycophenolic acid—psoriasis	7.69e-05	0.000144	CcSEcCtD
Tramadol—Pain—Prednisolone—psoriasis	7.69e-05	0.000144	CcSEcCtD
Tramadol—Hepatitis—Methotrexate—psoriasis	7.68e-05	0.000144	CcSEcCtD
Tramadol—Haemorrhage—Methotrexate—psoriasis	7.68e-05	0.000144	CcSEcCtD
Tramadol—Urticaria—Mycophenolate mofetil—psoriasis	7.65e-05	0.000144	CcSEcCtD
Tramadol—Headache—Mycophenolic acid—psoriasis	7.65e-05	0.000144	CcSEcCtD
Tramadol—Decreased appetite—Hydrocortisone—psoriasis	7.63e-05	0.000143	CcSEcCtD
Tramadol—Pharyngitis—Methotrexate—psoriasis	7.63e-05	0.000143	CcSEcCtD
Tramadol—Body temperature increased—Mycophenolate mofetil—psoriasis	7.62e-05	0.000143	CcSEcCtD
Tramadol—Abdominal pain—Mycophenolate mofetil—psoriasis	7.62e-05	0.000143	CcSEcCtD
Tramadol—Urinary tract disorder—Methotrexate—psoriasis	7.59e-05	0.000143	CcSEcCtD
Tramadol—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.58e-05	0.000142	CcSEcCtD
Tramadol—Fatigue—Hydrocortisone—psoriasis	7.57e-05	0.000142	CcSEcCtD
Tramadol—Vision blurred—Prednisone—psoriasis	7.54e-05	0.000142	CcSEcCtD
Tramadol—Urethral disorder—Methotrexate—psoriasis	7.53e-05	0.000141	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.53e-05	0.000141	CcSEcCtD
Tramadol—Pain—Hydrocortisone—psoriasis	7.51e-05	0.000141	CcSEcCtD
Tramadol—Anaphylactic shock—Betamethasone—psoriasis	7.5e-05	0.000141	CcSEcCtD
Tramadol—Anaphylactic shock—Dexamethasone—psoriasis	7.5e-05	0.000141	CcSEcCtD
Tramadol—OPRD1—GPCR ligand binding—CCL20—psoriasis	7.48e-05	0.00473	CbGpPWpGaD
Tramadol—Insomnia—Triamcinolone—psoriasis	7.48e-05	0.00014	CcSEcCtD
Tramadol—OPRM1—TCR Signaling Pathway—NFKBIA—psoriasis	7.47e-05	0.00472	CbGpPWpGaD
Tramadol—Infection—Dexamethasone—psoriasis	7.45e-05	0.00014	CcSEcCtD
Tramadol—Infection—Betamethasone—psoriasis	7.45e-05	0.00014	CcSEcCtD
Tramadol—Ill-defined disorder—Prednisone—psoriasis	7.43e-05	0.000139	CcSEcCtD
Tramadol—Paraesthesia—Triamcinolone—psoriasis	7.42e-05	0.000139	CcSEcCtD
Tramadol—Feeling abnormal—Prednisolone—psoriasis	7.41e-05	0.000139	CcSEcCtD
Tramadol—Visual impairment—Methotrexate—psoriasis	7.4e-05	0.000139	CcSEcCtD
Tramadol—Anaemia—Prednisone—psoriasis	7.4e-05	0.000139	CcSEcCtD
Tramadol—OPRD1—Signaling by GPCR—HCAR2—psoriasis	7.39e-05	0.00467	CbGpPWpGaD
Tramadol—Shock—Betamethasone—psoriasis	7.38e-05	0.000139	CcSEcCtD
Tramadol—Shock—Dexamethasone—psoriasis	7.38e-05	0.000139	CcSEcCtD
Tramadol—Dyspnoea—Triamcinolone—psoriasis	7.37e-05	0.000138	CcSEcCtD
Tramadol—Nervous system disorder—Dexamethasone—psoriasis	7.35e-05	0.000138	CcSEcCtD
Tramadol—Nervous system disorder—Betamethasone—psoriasis	7.35e-05	0.000138	CcSEcCtD
Tramadol—Agitation—Prednisone—psoriasis	7.35e-05	0.000138	CcSEcCtD
Tramadol—Thrombocytopenia—Betamethasone—psoriasis	7.34e-05	0.000138	CcSEcCtD
Tramadol—Thrombocytopenia—Dexamethasone—psoriasis	7.34e-05	0.000138	CcSEcCtD
Tramadol—Tachycardia—Dexamethasone—psoriasis	7.32e-05	0.000138	CcSEcCtD
Tramadol—Tachycardia—Betamethasone—psoriasis	7.32e-05	0.000138	CcSEcCtD
Tramadol—Angioedema—Prednisone—psoriasis	7.31e-05	0.000137	CcSEcCtD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.28e-05	0.0046	CbGpPWpGaD
Tramadol—Hypersensitivity—Cyclosporine—psoriasis	7.28e-05	0.000137	CcSEcCtD
Tramadol—Dyspepsia—Triamcinolone—psoriasis	7.28e-05	0.000137	CcSEcCtD
Tramadol—Erythema multiforme—Methotrexate—psoriasis	7.26e-05	0.000136	CcSEcCtD
Tramadol—Nausea—Mycophenolic acid—psoriasis	7.25e-05	0.000136	CcSEcCtD
Tramadol—Hyperhidrosis—Betamethasone—psoriasis	7.25e-05	0.000136	CcSEcCtD
Tramadol—Hyperhidrosis—Dexamethasone—psoriasis	7.25e-05	0.000136	CcSEcCtD
Tramadol—Feeling abnormal—Hydrocortisone—psoriasis	7.23e-05	0.000136	CcSEcCtD
Tramadol—Malaise—Prednisone—psoriasis	7.22e-05	0.000136	CcSEcCtD
Tramadol—Vertigo—Prednisone—psoriasis	7.19e-05	0.000135	CcSEcCtD
Tramadol—Eye disorder—Methotrexate—psoriasis	7.18e-05	0.000135	CcSEcCtD
Tramadol—Gastrointestinal pain—Hydrocortisone—psoriasis	7.18e-05	0.000135	CcSEcCtD
Tramadol—Syncope—Prednisone—psoriasis	7.18e-05	0.000135	CcSEcCtD
Tramadol—Tinnitus—Methotrexate—psoriasis	7.16e-05	0.000135	CcSEcCtD
Tramadol—Anorexia—Betamethasone—psoriasis	7.15e-05	0.000134	CcSEcCtD
Tramadol—Anorexia—Dexamethasone—psoriasis	7.15e-05	0.000134	CcSEcCtD
Tramadol—Urticaria—Prednisolone—psoriasis	7.14e-05	0.000134	CcSEcCtD
Tramadol—OPRK1—GPCR downstream signaling—HCAR2—psoriasis	7.14e-05	0.00451	CbGpPWpGaD
Tramadol—Cardiac disorder—Methotrexate—psoriasis	7.13e-05	0.000134	CcSEcCtD
Tramadol—Fatigue—Triamcinolone—psoriasis	7.13e-05	0.000134	CcSEcCtD
Tramadol—Hypersensitivity—Mycophenolate mofetil—psoriasis	7.1e-05	0.000133	CcSEcCtD
Tramadol—Asthenia—Cyclosporine—psoriasis	7.09e-05	0.000133	CcSEcCtD
Tramadol—Pain—Triamcinolone—psoriasis	7.07e-05	0.000133	CcSEcCtD
Tramadol—Loss of consciousness—Prednisone—psoriasis	7.03e-05	0.000132	CcSEcCtD
Tramadol—Hypotension—Dexamethasone—psoriasis	7.01e-05	0.000132	CcSEcCtD
Tramadol—Hypotension—Betamethasone—psoriasis	7.01e-05	0.000132	CcSEcCtD
Tramadol—Pruritus—Cyclosporine—psoriasis	6.99e-05	0.000131	CcSEcCtD
Tramadol—Urticaria—Hydrocortisone—psoriasis	6.97e-05	0.000131	CcSEcCtD
Tramadol—Angiopathy—Methotrexate—psoriasis	6.97e-05	0.000131	CcSEcCtD
Tramadol—Immune system disorder—Methotrexate—psoriasis	6.94e-05	0.00013	CcSEcCtD
Tramadol—Abdominal pain—Hydrocortisone—psoriasis	6.94e-05	0.00013	CcSEcCtD
Tramadol—Body temperature increased—Hydrocortisone—psoriasis	6.94e-05	0.00013	CcSEcCtD
Tramadol—Convulsion—Prednisone—psoriasis	6.93e-05	0.00013	CcSEcCtD
Tramadol—Mediastinal disorder—Methotrexate—psoriasis	6.92e-05	0.00013	CcSEcCtD
Tramadol—Asthenia—Mycophenolate mofetil—psoriasis	6.91e-05	0.00013	CcSEcCtD
Tramadol—Hypertension—Prednisone—psoriasis	6.91e-05	0.00013	CcSEcCtD
Tramadol—Chills—Methotrexate—psoriasis	6.89e-05	0.00013	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Betamethasone—psoriasis	6.83e-05	0.000128	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.83e-05	0.000128	CcSEcCtD
Tramadol—Pruritus—Mycophenolate mofetil—psoriasis	6.82e-05	0.000128	CcSEcCtD
Tramadol—Myalgia—Prednisone—psoriasis	6.81e-05	0.000128	CcSEcCtD
Tramadol—Arthralgia—Prednisone—psoriasis	6.81e-05	0.000128	CcSEcCtD
Tramadol—Feeling abnormal—Triamcinolone—psoriasis	6.81e-05	0.000128	CcSEcCtD
Tramadol—Anxiety—Prednisone—psoriasis	6.79e-05	0.000128	CcSEcCtD
Tramadol—Insomnia—Dexamethasone—psoriasis	6.78e-05	0.000127	CcSEcCtD
Tramadol—Insomnia—Betamethasone—psoriasis	6.78e-05	0.000127	CcSEcCtD
Tramadol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.77e-05	0.000127	CcSEcCtD
Tramadol—Diarrhoea—Cyclosporine—psoriasis	6.76e-05	0.000127	CcSEcCtD
Tramadol—Paraesthesia—Dexamethasone—psoriasis	6.73e-05	0.000127	CcSEcCtD
Tramadol—Paraesthesia—Betamethasone—psoriasis	6.73e-05	0.000127	CcSEcCtD
Tramadol—Discomfort—Prednisone—psoriasis	6.73e-05	0.000126	CcSEcCtD
Tramadol—Mental disorder—Methotrexate—psoriasis	6.73e-05	0.000126	CcSEcCtD
Tramadol—Erythema—Methotrexate—psoriasis	6.69e-05	0.000126	CcSEcCtD
Tramadol—Malnutrition—Methotrexate—psoriasis	6.69e-05	0.000126	CcSEcCtD
Tramadol—Hypersensitivity—Prednisolone—psoriasis	6.62e-05	0.000124	CcSEcCtD
Tramadol—Dyspepsia—Dexamethasone—psoriasis	6.6e-05	0.000124	CcSEcCtD
Tramadol—Dyspepsia—Betamethasone—psoriasis	6.6e-05	0.000124	CcSEcCtD
Tramadol—Diarrhoea—Mycophenolate mofetil—psoriasis	6.59e-05	0.000124	CcSEcCtD
Tramadol—Urticaria—Triamcinolone—psoriasis	6.57e-05	0.000123	CcSEcCtD
Tramadol—OPRK1—GPCR ligand binding—CCL20—psoriasis	6.56e-05	0.00414	CbGpPWpGaD
Tramadol—Dysgeusia—Methotrexate—psoriasis	6.55e-05	0.000123	CcSEcCtD
Tramadol—Body temperature increased—Triamcinolone—psoriasis	6.53e-05	0.000123	CcSEcCtD
Tramadol—Dizziness—Cyclosporine—psoriasis	6.53e-05	0.000123	CcSEcCtD
Tramadol—Anaphylactic shock—Prednisone—psoriasis	6.53e-05	0.000123	CcSEcCtD
Tramadol—Decreased appetite—Dexamethasone—psoriasis	6.52e-05	0.000122	CcSEcCtD
Tramadol—Decreased appetite—Betamethasone—psoriasis	6.52e-05	0.000122	CcSEcCtD
Tramadol—Infection—Prednisone—psoriasis	6.49e-05	0.000122	CcSEcCtD
Tramadol—OPRK1—Signaling by GPCR—HCAR2—psoriasis	6.48e-05	0.00409	CbGpPWpGaD
Tramadol—Gastrointestinal disorder—Betamethasone—psoriasis	6.47e-05	0.000122	CcSEcCtD
Tramadol—Gastrointestinal disorder—Dexamethasone—psoriasis	6.47e-05	0.000122	CcSEcCtD
Tramadol—Back pain—Methotrexate—psoriasis	6.47e-05	0.000122	CcSEcCtD
Tramadol—Hypersensitivity—Hydrocortisone—psoriasis	6.47e-05	0.000122	CcSEcCtD
Tramadol—Fatigue—Dexamethasone—psoriasis	6.47e-05	0.000121	CcSEcCtD
Tramadol—Fatigue—Betamethasone—psoriasis	6.47e-05	0.000121	CcSEcCtD
Tramadol—Shock—Prednisone—psoriasis	6.43e-05	0.000121	CcSEcCtD
Tramadol—Pain—Betamethasone—psoriasis	6.41e-05	0.00012	CcSEcCtD
Tramadol—Pain—Dexamethasone—psoriasis	6.41e-05	0.00012	CcSEcCtD
Tramadol—Nervous system disorder—Prednisone—psoriasis	6.41e-05	0.00012	CcSEcCtD
Tramadol—Tachycardia—Prednisone—psoriasis	6.37e-05	0.00012	CcSEcCtD
Tramadol—Dizziness—Mycophenolate mofetil—psoriasis	6.37e-05	0.00012	CcSEcCtD
Tramadol—Skin disorder—Prednisone—psoriasis	6.34e-05	0.000119	CcSEcCtD
Tramadol—Hyperhidrosis—Prednisone—psoriasis	6.31e-05	0.000119	CcSEcCtD
Tramadol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	6.31e-05	0.00399	CbGpPWpGaD
Tramadol—Vision blurred—Methotrexate—psoriasis	6.3e-05	0.000118	CcSEcCtD
Tramadol—Asthenia—Hydrocortisone—psoriasis	6.3e-05	0.000118	CcSEcCtD
Tramadol—Vomiting—Cyclosporine—psoriasis	6.28e-05	0.000118	CcSEcCtD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.25e-05	0.00395	CbGpPWpGaD
Tramadol—Rash—Cyclosporine—psoriasis	6.23e-05	0.000117	CcSEcCtD
Tramadol—Anorexia—Prednisone—psoriasis	6.23e-05	0.000117	CcSEcCtD
Tramadol—Dermatitis—Cyclosporine—psoriasis	6.22e-05	0.000117	CcSEcCtD
Tramadol—Pruritus—Hydrocortisone—psoriasis	6.21e-05	0.000117	CcSEcCtD
Tramadol—Ill-defined disorder—Methotrexate—psoriasis	6.21e-05	0.000117	CcSEcCtD
Tramadol—Headache—Cyclosporine—psoriasis	6.19e-05	0.000116	CcSEcCtD
Tramadol—Anaemia—Methotrexate—psoriasis	6.18e-05	0.000116	CcSEcCtD
Tramadol—Feeling abnormal—Dexamethasone—psoriasis	6.18e-05	0.000116	CcSEcCtD
Tramadol—Feeling abnormal—Betamethasone—psoriasis	6.18e-05	0.000116	CcSEcCtD
Tramadol—Gastrointestinal pain—Betamethasone—psoriasis	6.13e-05	0.000115	CcSEcCtD
Tramadol—Gastrointestinal pain—Dexamethasone—psoriasis	6.13e-05	0.000115	CcSEcCtD
Tramadol—Vomiting—Mycophenolate mofetil—psoriasis	6.13e-05	0.000115	CcSEcCtD
Tramadol—Hypersensitivity—Triamcinolone—psoriasis	6.09e-05	0.000114	CcSEcCtD
Tramadol—Rash—Mycophenolate mofetil—psoriasis	6.08e-05	0.000114	CcSEcCtD
Tramadol—Dermatitis—Mycophenolate mofetil—psoriasis	6.07e-05	0.000114	CcSEcCtD
Tramadol—Headache—Mycophenolate mofetil—psoriasis	6.04e-05	0.000113	CcSEcCtD
Tramadol—OPRM1—GPCR downstream signaling—HCAR2—psoriasis	6.03e-05	0.00381	CbGpPWpGaD
Tramadol—Malaise—Methotrexate—psoriasis	6.03e-05	0.000113	CcSEcCtD
Tramadol—Vertigo—Methotrexate—psoriasis	6.01e-05	0.000113	CcSEcCtD
Tramadol—Diarrhoea—Hydrocortisone—psoriasis	6.01e-05	0.000113	CcSEcCtD
Tramadol—Urticaria—Dexamethasone—psoriasis	5.96e-05	0.000112	CcSEcCtD
Tramadol—Urticaria—Betamethasone—psoriasis	5.96e-05	0.000112	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Prednisone—psoriasis	5.95e-05	0.000112	CcSEcCtD
Tramadol—Dizziness—Prednisolone—psoriasis	5.94e-05	0.000112	CcSEcCtD
Tramadol—Asthenia—Triamcinolone—psoriasis	5.93e-05	0.000111	CcSEcCtD
Tramadol—Body temperature increased—Dexamethasone—psoriasis	5.93e-05	0.000111	CcSEcCtD
Tramadol—Body temperature increased—Betamethasone—psoriasis	5.93e-05	0.000111	CcSEcCtD
Tramadol—Abdominal pain—Dexamethasone—psoriasis	5.93e-05	0.000111	CcSEcCtD
Tramadol—Abdominal pain—Betamethasone—psoriasis	5.93e-05	0.000111	CcSEcCtD
Tramadol—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.92e-05	0.00374	CbGpPWpGaD
Tramadol—Insomnia—Prednisone—psoriasis	5.91e-05	0.000111	CcSEcCtD
Tramadol—Nausea—Cyclosporine—psoriasis	5.87e-05	0.00011	CcSEcCtD
Tramadol—Paraesthesia—Prednisone—psoriasis	5.86e-05	0.00011	CcSEcCtD
Tramadol—Pruritus—Triamcinolone—psoriasis	5.85e-05	0.00011	CcSEcCtD
Tramadol—Cough—Methotrexate—psoriasis	5.84e-05	0.00011	CcSEcCtD
Tramadol—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.84e-05	0.00369	CbGpPWpGaD
Tramadol—Dizziness—Hydrocortisone—psoriasis	5.8e-05	0.000109	CcSEcCtD
Tramadol—Convulsion—Methotrexate—psoriasis	5.79e-05	0.000109	CcSEcCtD
Tramadol—Dyspepsia—Prednisone—psoriasis	5.75e-05	0.000108	CcSEcCtD
Tramadol—Nausea—Mycophenolate mofetil—psoriasis	5.72e-05	0.000108	CcSEcCtD
Tramadol—Chest pain—Methotrexate—psoriasis	5.69e-05	0.000107	CcSEcCtD
Tramadol—Myalgia—Methotrexate—psoriasis	5.69e-05	0.000107	CcSEcCtD
Tramadol—Arthralgia—Methotrexate—psoriasis	5.69e-05	0.000107	CcSEcCtD
Tramadol—Decreased appetite—Prednisone—psoriasis	5.68e-05	0.000107	CcSEcCtD
Tramadol—Rash—Prednisolone—psoriasis	5.67e-05	0.000106	CcSEcCtD
Tramadol—Dermatitis—Prednisolone—psoriasis	5.66e-05	0.000106	CcSEcCtD
Tramadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.65e-05	0.000106	CcSEcCtD
Tramadol—Fatigue—Prednisone—psoriasis	5.63e-05	0.000106	CcSEcCtD
Tramadol—Headache—Prednisolone—psoriasis	5.63e-05	0.000106	CcSEcCtD
Tramadol—Discomfort—Methotrexate—psoriasis	5.63e-05	0.000106	CcSEcCtD
Tramadol—Constipation—Prednisone—psoriasis	5.59e-05	0.000105	CcSEcCtD
Tramadol—Vomiting—Hydrocortisone—psoriasis	5.58e-05	0.000105	CcSEcCtD
Tramadol—OPRM1—GPCR ligand binding—CCL20—psoriasis	5.55e-05	0.0035	CbGpPWpGaD
Tramadol—OPRM1—TCR Signaling Pathway—CD4—psoriasis	5.54e-05	0.0035	CbGpPWpGaD
Tramadol—Rash—Hydrocortisone—psoriasis	5.53e-05	0.000104	CcSEcCtD
Tramadol—Dermatitis—Hydrocortisone—psoriasis	5.53e-05	0.000104	CcSEcCtD
Tramadol—Confusional state—Methotrexate—psoriasis	5.5e-05	0.000103	CcSEcCtD
Tramadol—Headache—Hydrocortisone—psoriasis	5.5e-05	0.000103	CcSEcCtD
Tramadol—OPRM1—Signaling by GPCR—HCAR2—psoriasis	5.48e-05	0.00346	CbGpPWpGaD
Tramadol—Dizziness—Triamcinolone—psoriasis	5.47e-05	0.000103	CcSEcCtD
Tramadol—Anaphylactic shock—Methotrexate—psoriasis	5.46e-05	0.000103	CcSEcCtD
Tramadol—Infection—Methotrexate—psoriasis	5.42e-05	0.000102	CcSEcCtD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	5.38e-05	0.0034	CbGpPWpGaD
Tramadol—Feeling abnormal—Prednisone—psoriasis	5.38e-05	0.000101	CcSEcCtD
Tramadol—Asthenia—Dexamethasone—psoriasis	5.38e-05	0.000101	CcSEcCtD
Tramadol—Asthenia—Betamethasone—psoriasis	5.38e-05	0.000101	CcSEcCtD
Tramadol—Nervous system disorder—Methotrexate—psoriasis	5.35e-05	0.000101	CcSEcCtD
Tramadol—Thrombocytopenia—Methotrexate—psoriasis	5.34e-05	0.0001	CcSEcCtD
Tramadol—Gastrointestinal pain—Prednisone—psoriasis	5.34e-05	0.0001	CcSEcCtD
Tramadol—Nausea—Prednisolone—psoriasis	5.34e-05	0.0001	CcSEcCtD
Tramadol—Pruritus—Betamethasone—psoriasis	5.31e-05	9.97e-05	CcSEcCtD
Tramadol—Pruritus—Dexamethasone—psoriasis	5.31e-05	9.97e-05	CcSEcCtD
Tramadol—Skin disorder—Methotrexate—psoriasis	5.3e-05	9.96e-05	CcSEcCtD
Tramadol—Hyperhidrosis—Methotrexate—psoriasis	5.28e-05	9.91e-05	CcSEcCtD
Tramadol—Vomiting—Triamcinolone—psoriasis	5.26e-05	9.87e-05	CcSEcCtD
Tramadol—SLC6A4—Circadian rythm related genes—LEP—psoriasis	5.23e-05	0.0033	CbGpPWpGaD
Tramadol—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	5.22e-05	0.0033	CbGpPWpGaD
Tramadol—Nausea—Hydrocortisone—psoriasis	5.21e-05	9.8e-05	CcSEcCtD
Tramadol—Rash—Triamcinolone—psoriasis	5.21e-05	9.79e-05	CcSEcCtD
Tramadol—Dermatitis—Triamcinolone—psoriasis	5.21e-05	9.78e-05	CcSEcCtD
Tramadol—Anorexia—Methotrexate—psoriasis	5.2e-05	9.77e-05	CcSEcCtD
Tramadol—Urticaria—Prednisone—psoriasis	5.19e-05	9.75e-05	CcSEcCtD
Tramadol—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	5.18e-05	0.00327	CbGpPWpGaD
Tramadol—Headache—Triamcinolone—psoriasis	5.18e-05	9.73e-05	CcSEcCtD
Tramadol—Body temperature increased—Prednisone—psoriasis	5.16e-05	9.7e-05	CcSEcCtD
Tramadol—Abdominal pain—Prednisone—psoriasis	5.16e-05	9.7e-05	CcSEcCtD
Tramadol—Diarrhoea—Dexamethasone—psoriasis	5.13e-05	9.64e-05	CcSEcCtD
Tramadol—Diarrhoea—Betamethasone—psoriasis	5.13e-05	9.64e-05	CcSEcCtD
Tramadol—CYP3A4—Tryptophan metabolism—CAT—psoriasis	5.1e-05	0.00322	CbGpPWpGaD
Tramadol—Hypotension—Methotrexate—psoriasis	5.1e-05	9.58e-05	CcSEcCtD
Tramadol—Musculoskeletal discomfort—Methotrexate—psoriasis	4.97e-05	9.34e-05	CcSEcCtD
Tramadol—Dizziness—Betamethasone—psoriasis	4.96e-05	9.32e-05	CcSEcCtD
Tramadol—Dizziness—Dexamethasone—psoriasis	4.96e-05	9.32e-05	CcSEcCtD
Tramadol—OPRM1—TCR Signaling Pathway—JUN—psoriasis	4.96e-05	0.00313	CbGpPWpGaD
Tramadol—Insomnia—Methotrexate—psoriasis	4.94e-05	9.27e-05	CcSEcCtD
Tramadol—Nausea—Triamcinolone—psoriasis	4.91e-05	9.22e-05	CcSEcCtD
Tramadol—Paraesthesia—Methotrexate—psoriasis	4.9e-05	9.21e-05	CcSEcCtD
Tramadol—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	4.87e-05	0.00308	CbGpPWpGaD
Tramadol—Dyspnoea—Methotrexate—psoriasis	4.87e-05	9.14e-05	CcSEcCtD
Tramadol—Somnolence—Methotrexate—psoriasis	4.85e-05	9.12e-05	CcSEcCtD
Tramadol—Hypersensitivity—Prednisone—psoriasis	4.81e-05	9.04e-05	CcSEcCtD
Tramadol—Dyspepsia—Methotrexate—psoriasis	4.8e-05	9.03e-05	CcSEcCtD
Tramadol—OPRM1—TCR Signaling Pathway—NFKB1—psoriasis	4.77e-05	0.00301	CbGpPWpGaD
Tramadol—Vomiting—Dexamethasone—psoriasis	4.77e-05	8.96e-05	CcSEcCtD
Tramadol—Vomiting—Betamethasone—psoriasis	4.77e-05	8.96e-05	CcSEcCtD
Tramadol—HTR2C—GPCR ligand binding—CCL20—psoriasis	4.76e-05	0.00301	CbGpPWpGaD
Tramadol—Decreased appetite—Methotrexate—psoriasis	4.74e-05	8.91e-05	CcSEcCtD
Tramadol—Rash—Dexamethasone—psoriasis	4.73e-05	8.88e-05	CcSEcCtD
Tramadol—Rash—Betamethasone—psoriasis	4.73e-05	8.88e-05	CcSEcCtD
Tramadol—Dermatitis—Dexamethasone—psoriasis	4.72e-05	8.88e-05	CcSEcCtD
Tramadol—Dermatitis—Betamethasone—psoriasis	4.72e-05	8.88e-05	CcSEcCtD
Tramadol—Gastrointestinal disorder—Methotrexate—psoriasis	4.71e-05	8.85e-05	CcSEcCtD
Tramadol—Fatigue—Methotrexate—psoriasis	4.71e-05	8.84e-05	CcSEcCtD
Tramadol—HTR2C—Signaling by GPCR—HCAR2—psoriasis	4.71e-05	0.00297	CbGpPWpGaD
Tramadol—Headache—Dexamethasone—psoriasis	4.7e-05	8.83e-05	CcSEcCtD
Tramadol—Headache—Betamethasone—psoriasis	4.7e-05	8.83e-05	CcSEcCtD
Tramadol—Asthenia—Prednisone—psoriasis	4.69e-05	8.8e-05	CcSEcCtD
Tramadol—Pain—Methotrexate—psoriasis	4.67e-05	8.77e-05	CcSEcCtD
Tramadol—Pruritus—Prednisone—psoriasis	4.62e-05	8.68e-05	CcSEcCtD
Tramadol—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	4.55e-05	0.00287	CbGpPWpGaD
Tramadol—Feeling abnormal—Methotrexate—psoriasis	4.5e-05	8.45e-05	CcSEcCtD
Tramadol—Diarrhoea—Prednisone—psoriasis	4.47e-05	8.4e-05	CcSEcCtD
Tramadol—Gastrointestinal pain—Methotrexate—psoriasis	4.46e-05	8.39e-05	CcSEcCtD
Tramadol—CHRM3—GPCR downstream signaling—HCAR2—psoriasis	4.46e-05	0.00282	CbGpPWpGaD
Tramadol—Nausea—Dexamethasone—psoriasis	4.45e-05	8.37e-05	CcSEcCtD
Tramadol—Nausea—Betamethasone—psoriasis	4.45e-05	8.37e-05	CcSEcCtD
Tramadol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	4.4e-05	0.00278	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—HCAR2—psoriasis	4.37e-05	0.00276	CbGpPWpGaD
Tramadol—Urticaria—Methotrexate—psoriasis	4.34e-05	8.15e-05	CcSEcCtD
Tramadol—Dizziness—Prednisone—psoriasis	4.32e-05	8.11e-05	CcSEcCtD
Tramadol—Abdominal pain—Methotrexate—psoriasis	4.31e-05	8.11e-05	CcSEcCtD
Tramadol—Body temperature increased—Methotrexate—psoriasis	4.31e-05	8.11e-05	CcSEcCtD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.25e-05	0.00269	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CCL20—psoriasis	4.23e-05	0.00267	CbGpPWpGaD
Tramadol—Vomiting—Prednisone—psoriasis	4.15e-05	7.8e-05	CcSEcCtD
Tramadol—Rash—Prednisone—psoriasis	4.12e-05	7.74e-05	CcSEcCtD
Tramadol—Dermatitis—Prednisone—psoriasis	4.11e-05	7.73e-05	CcSEcCtD
Tramadol—CHRM3—GPCR ligand binding—CCL20—psoriasis	4.1e-05	0.00259	CbGpPWpGaD
Tramadol—Headache—Prednisone—psoriasis	4.09e-05	7.69e-05	CcSEcCtD
Tramadol—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	4.08e-05	0.00257	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—HCAR2—psoriasis	4.05e-05	0.00256	CbGpPWpGaD
Tramadol—Hypersensitivity—Methotrexate—psoriasis	4.02e-05	7.56e-05	CcSEcCtD
Tramadol—OPRD1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.96e-05	0.0025	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	3.95e-05	0.0025	CbGpPWpGaD
Tramadol—Asthenia—Methotrexate—psoriasis	3.92e-05	7.36e-05	CcSEcCtD
Tramadol—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	3.89e-05	0.00246	CbGpPWpGaD
Tramadol—Nausea—Prednisone—psoriasis	3.88e-05	7.29e-05	CcSEcCtD
Tramadol—Pruritus—Methotrexate—psoriasis	3.86e-05	7.26e-05	CcSEcCtD
Tramadol—OPRD1—Signaling by GPCR—CCL20—psoriasis	3.84e-05	0.00243	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—HCAR2—psoriasis	3.83e-05	0.00242	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	3.81e-05	0.0024	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—TAGAP—psoriasis	3.79e-05	0.00239	CbGpPWpGaD
Tramadol—Diarrhoea—Methotrexate—psoriasis	3.73e-05	7.02e-05	CcSEcCtD
Tramadol—OPRK1—GPCR downstream signaling—CCL20—psoriasis	3.71e-05	0.00234	CbGpPWpGaD
Tramadol—Dizziness—Methotrexate—psoriasis	3.61e-05	6.78e-05	CcSEcCtD
Tramadol—Vomiting—Methotrexate—psoriasis	3.47e-05	6.52e-05	CcSEcCtD
Tramadol—OPRK1—Peptide ligand-binding receptors—CXCL8—psoriasis	3.47e-05	0.00219	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.45e-05	0.00218	CbGpPWpGaD
Tramadol—Rash—Methotrexate—psoriasis	3.44e-05	6.47e-05	CcSEcCtD
Tramadol—Dermatitis—Methotrexate—psoriasis	3.44e-05	6.46e-05	CcSEcCtD
Tramadol—Headache—Methotrexate—psoriasis	3.42e-05	6.42e-05	CcSEcCtD
Tramadol—OPRK1—Signaling by GPCR—CCL20—psoriasis	3.37e-05	0.00213	CbGpPWpGaD
Tramadol—OPRD1—G alpha (i) signalling events—CXCL8—psoriasis	3.34e-05	0.00211	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—TAGAP—psoriasis	3.32e-05	0.0021	CbGpPWpGaD
Tramadol—Nausea—Methotrexate—psoriasis	3.24e-05	6.09e-05	CcSEcCtD
Tramadol—OPRM1—Signaling Pathways—HCAR2—psoriasis	3.24e-05	0.00204	CbGpPWpGaD
Tramadol—SLC6A4—Circadian rythm related genes—JUN—psoriasis	3.23e-05	0.00204	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CCL20—psoriasis	3.13e-05	0.00198	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—NDUFA5—psoriasis	3.04e-05	0.00192	CbGpPWpGaD
Tramadol—OPRM1—TCR Signaling Pathway—IL6—psoriasis	2.99e-05	0.00189	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	2.96e-05	0.00187	CbGpPWpGaD
Tramadol—OPRM1—Peptide ligand-binding receptors—CXCL8—psoriasis	2.93e-05	0.00185	CbGpPWpGaD
Tramadol—OPRK1—G alpha (i) signalling events—CXCL8—psoriasis	2.93e-05	0.00185	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CCL20—psoriasis	2.85e-05	0.0018	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—TAGAP—psoriasis	2.81e-05	0.00177	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—HCAR2—psoriasis	2.78e-05	0.00176	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CCL20—psoriasis	2.69e-05	0.0017	CbGpPWpGaD
Tramadol—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.65e-05	0.00168	CbGpPWpGaD
Tramadol—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.62e-05	0.00165	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—NDUFA5—psoriasis	2.62e-05	0.00165	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—CYP2S1—psoriasis	2.59e-05	0.00163	CbGpPWpGaD
Tramadol—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	2.47e-05	0.00156	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CCL20—psoriasis	2.44e-05	0.00154	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—TAGAP—psoriasis	2.41e-05	0.00152	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—HCAR2—psoriasis	2.39e-05	0.00151	CbGpPWpGaD
Tramadol—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	2.39e-05	0.00151	CbGpPWpGaD
Tramadol—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.33e-05	0.00147	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CCL20—psoriasis	2.32e-05	0.00146	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CCL20—psoriasis	2.27e-05	0.00143	CbGpPWpGaD
Tramadol—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.26e-05	0.00142	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—CYP2S1—psoriasis	2.23e-05	0.00141	CbGpPWpGaD
Tramadol—SLC6A4—Circadian rythm related genes—TP53—psoriasis	2.13e-05	0.00135	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CCL20—psoriasis	2.1e-05	0.00133	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—TAGAP—psoriasis	2.07e-05	0.00131	CbGpPWpGaD
Tramadol—OPRD1—GPCR ligand binding—CXCL8—psoriasis	2.02e-05	0.00128	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CCL20—psoriasis	1.99e-05	0.00126	CbGpPWpGaD
Tramadol—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.97e-05	0.00124	CbGpPWpGaD
Tramadol—SLC6A4—Circadian rythm related genes—IL6—psoriasis	1.95e-05	0.00123	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—NDUFA5—psoriasis	1.82e-05	0.00115	CbGpPWpGaD
Tramadol—OPRK1—GPCR ligand binding—CXCL8—psoriasis	1.77e-05	0.00112	CbGpPWpGaD
Tramadol—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.69e-05	0.00107	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CCL20—psoriasis	1.68e-05	0.00106	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—CYP2S1—psoriasis	1.55e-05	0.000977	CbGpPWpGaD
Tramadol—OPRM1—GPCR ligand binding—CXCL8—psoriasis	1.5e-05	0.000946	CbGpPWpGaD
Tramadol—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.45e-05	0.000918	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CCL20—psoriasis	1.44e-05	0.000912	CbGpPWpGaD
Tramadol—HTR2C—GPCR ligand binding—CXCL8—psoriasis	1.29e-05	0.000812	CbGpPWpGaD
Tramadol—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.28e-05	0.000809	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—CARM1—psoriasis	1.26e-05	0.000798	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—SOCS1—psoriasis	1.25e-05	0.000789	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CCL20—psoriasis	1.24e-05	0.000785	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—TYK2—psoriasis	1.19e-05	0.000752	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—NDUFA5—psoriasis	1.19e-05	0.000752	CbGpPWpGaD
Tramadol—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	1.14e-05	0.000721	CbGpPWpGaD
Tramadol—CHRM3—GPCR ligand binding—CXCL8—psoriasis	1.11e-05	0.000699	CbGpPWpGaD
Tramadol—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.1e-05	0.000697	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—SOCS1—psoriasis	1.1e-05	0.000692	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—CARM1—psoriasis	1.09e-05	0.000687	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—TYK2—psoriasis	1.04e-05	0.00066	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—CXCL8—psoriasis	1.04e-05	0.000655	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—CYP2S1—psoriasis	1.01e-05	0.000639	CbGpPWpGaD
Tramadol—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	1e-05	0.000632	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—SOCS1—psoriasis	9.26e-06	0.000585	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—APOE—psoriasis	9.22e-06	0.000582	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—LEP—psoriasis	9.22e-06	0.000582	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—CXCL8—psoriasis	9.09e-06	0.000574	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—TYK2—psoriasis	8.83e-06	0.000558	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—NFKBIA—psoriasis	8.59e-06	0.000543	CbGpPWpGaD
Tramadol—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	8.46e-06	0.000535	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—APOE—psoriasis	8.08e-06	0.000511	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—LEP—psoriasis	8.08e-06	0.000511	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—SOCS1—psoriasis	7.95e-06	0.000502	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—CAT—psoriasis	7.77e-06	0.000491	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—CXCL8—psoriasis	7.69e-06	0.000485	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—TYK2—psoriasis	7.58e-06	0.000479	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—CARM1—psoriasis	7.56e-06	0.000477	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—NFKBIA—psoriasis	7.53e-06	0.000476	CbGpPWpGaD
Tramadol—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	7.27e-06	0.000459	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—TYK2—psoriasis	7.04e-06	0.000444	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—SOCS1—psoriasis	6.84e-06	0.000432	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—LEP—psoriasis	6.83e-06	0.000432	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—APOE—psoriasis	6.83e-06	0.000432	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—CAT—psoriasis	6.69e-06	0.000422	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—CXCL8—psoriasis	6.6e-06	0.000417	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—TYK2—psoriasis	6.53e-06	0.000412	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—NFKBIA—psoriasis	6.37e-06	0.000402	CbGpPWpGaD
Tramadol—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	6.26e-06	0.000395	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—TYK2—psoriasis	6.17e-06	0.00039	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—CXCL8—psoriasis	6.13e-06	0.000387	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—APOE—psoriasis	6.04e-06	0.000382	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—LEP—psoriasis	5.87e-06	0.000371	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—APOE—psoriasis	5.87e-06	0.000371	CbGpPWpGaD
Tramadol—OPRD1—Signaling by GPCR—IL6—psoriasis	5.83e-06	0.000368	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—JUN—psoriasis	5.7e-06	0.00036	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—CXCL8—psoriasis	5.68e-06	0.000359	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—NFKB1—psoriasis	5.48e-06	0.000346	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—NFKBIA—psoriasis	5.47e-06	0.000345	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—CXCL8—psoriasis	5.37e-06	0.000339	CbGpPWpGaD
Tramadol—CHRM3—Metabolism—PPARG—psoriasis	5.26e-06	0.000332	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—TYK2—psoriasis	5.21e-06	0.000329	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—APOE—psoriasis	5.2e-06	0.000328	CbGpPWpGaD
Tramadol—OPRK1—Signaling by GPCR—IL6—psoriasis	5.11e-06	0.000323	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—APOE—psoriasis	5.05e-06	0.000319	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—LEP—psoriasis	5.05e-06	0.000319	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—JUN—psoriasis	4.99e-06	0.000315	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—VEGFA—psoriasis	4.98e-06	0.000314	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—CARM1—psoriasis	4.94e-06	0.000312	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—STAT3—psoriasis	4.93e-06	0.000311	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—NFKB1—psoriasis	4.81e-06	0.000304	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—NFKBIA—psoriasis	4.71e-06	0.000297	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—CAT—psoriasis	4.65e-06	0.000294	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—CXCL8—psoriasis	4.54e-06	0.000287	CbGpPWpGaD
Tramadol—CYP2B6—Metabolism—PPARG—psoriasis	4.53e-06	0.000286	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—TYK2—psoriasis	4.48e-06	0.000283	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—VEGFA—psoriasis	4.36e-06	0.000276	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—STAT3—psoriasis	4.32e-06	0.000273	CbGpPWpGaD
Tramadol—OPRM1—Signaling by GPCR—IL6—psoriasis	4.32e-06	0.000273	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—JUN—psoriasis	4.22e-06	0.000267	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—NFKB1—psoriasis	4.06e-06	0.000257	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—CXCL8—psoriasis	3.9e-06	0.000246	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—TYK2—psoriasis	3.86e-06	0.000244	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—TP53—psoriasis	3.76e-06	0.000237	CbGpPWpGaD
Tramadol—HTR2C—Signaling by GPCR—IL6—psoriasis	3.71e-06	0.000234	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—VEGFA—psoriasis	3.69e-06	0.000233	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—STAT3—psoriasis	3.65e-06	0.000231	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—JUN—psoriasis	3.62e-06	0.000229	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—APOE—psoriasis	3.61e-06	0.000228	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—NFKB1—psoriasis	3.49e-06	0.00022	CbGpPWpGaD
Tramadol—OPRD1—Signaling Pathways—IL6—psoriasis	3.44e-06	0.000217	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—CXCL8—psoriasis	3.36e-06	0.000212	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—TP53—psoriasis	3.3e-06	0.000208	CbGpPWpGaD
Tramadol—CHRM3—Signaling by GPCR—IL6—psoriasis	3.19e-06	0.000202	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—VEGFA—psoriasis	3.17e-06	0.0002	CbGpPWpGaD
Tramadol—CYP2D6—Metabolism—PPARG—psoriasis	3.15e-06	0.000199	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—STAT3—psoriasis	3.14e-06	0.000198	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—JUN—psoriasis	3.12e-06	0.000197	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—CAT—psoriasis	3.04e-06	0.000192	CbGpPWpGaD
Tramadol—OPRK1—Signaling Pathways—IL6—psoriasis	3.02e-06	0.000191	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—NFKB1—psoriasis	3e-06	0.00019	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—TP53—psoriasis	2.79e-06	0.000176	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—VEGFA—psoriasis	2.73e-06	0.000172	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—STAT3—psoriasis	2.7e-06	0.000171	CbGpPWpGaD
Tramadol—OPRM1—Signaling Pathways—IL6—psoriasis	2.55e-06	0.000161	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—TP53—psoriasis	2.39e-06	0.000151	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—APOE—psoriasis	2.36e-06	0.000149	CbGpPWpGaD
Tramadol—HTR2C—Signaling Pathways—IL6—psoriasis	2.19e-06	0.000138	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—TP53—psoriasis	2.06e-06	0.00013	CbGpPWpGaD
Tramadol—CYP3A4—Metabolism—PPARG—psoriasis	2.06e-06	0.00013	CbGpPWpGaD
Tramadol—CHRM3—Signaling Pathways—IL6—psoriasis	1.89e-06	0.000119	CbGpPWpGaD
